Impact of pharmacist's interventions on cost of drug therapy in intensive care unit
Open Access
- 1 June 2009
- journal article
- Published by SciELO Espana/Repisalud in Pharmacy Practice
- Vol. 7 (2), 81-87
- https://doi.org/10.4321/s1886-36552009000200003
Abstract
Pharmacist participation in patient care team has been shown to reduce incidence of adverse drug events, and overall drug costs. However, impact of pharmacist participation in the multidisciplinary intensive care team on cost saving and cost avoidance has little been studied in Thailand. To describe the characteristics of the interventions and to determine pharmacist's interventions led to change in cost saving and cost avoidance in intensive care unit (ICU). A Prospective, standard care-controlled study design was used to compare cost saving and cost avoidance of patients receiving care from patient care team (including a clinical pharmacist) versus standard care (no pharmacist on team). All patients admitted to the medical intensive care unit 1 and 2 during the same period were included in the study. The outcome measures were overall drug cost and length of ICU stay. Interventions made by the pharmacist in the study group were documented. The analyses of acceptance and cost saving and/or cost avoidance were also performed. A total of 65 patients were admitted to either ICU 1 or 2 during the 5 week-study period. The pharmacist participated in patient care and made total of 127 interventions for the ICU-1 team. Ninety-eight percent of the interventions were accepted and implemented by physicians. The difference of overall drug cost per patient between two groups was 182.01 USD (1,076.37 USD in study group and 1,258.38 USD in control group, p=0.138). The average length of ICU stay for the intervention group and the control group was not significantly different (7.16 days vs. 6.18 days, p=0.995). The 125 accepted interventions were evaluated for cost saving and cost avoidance. Pharmacist's interventions yielded a total of 1,971.43 USD from drug cost saving and 294.62 USD from adverse drug event cost avoidance. The net cost saved and avoided from pharmacist interventions was 2,266.05 USD. Interventions involving antibiotic use accounted for the largest economic impact (1,958.61 USD). Although the statistical was not significant, having a pharmacist participated in ICU patient care team tend to reduced overall drug cost, cost saving, and cost avoidance. The largest cost impact and intervention requirement involved antibiotic use.Keywords
This publication has 30 references indexed in Scilit:
- ASHP Guidelines on the Pharmacist’s Role in the Development, Implementation, and Assessment of Critical PathwaysAmerican Journal of Health-System Pharmacy, 2004
- Impact of a Pharmacist Consult Clinic on a Hospital-based Geriatric Outpatient Clinic in SingaporeAnnals of the Academy of Medicine, Singapore, 2004
- Pharmacists on Rounding Teams Reduce Preventable Adverse Drug Events in Hospital General Medicine UnitsArchives of Internal Medicine, 2003
- Linking Laboratory and PharmacyArchives of Internal Medicine, 2003
- Evaluation of pharmacists' services for hospital inpatients.American Journal of Health-System Pharmacy, 2002
- Economic evaluations of clinical pharmacy services--1988-1995. The Publications Committee of the American College of Clinical Pharmacy.1996
- Critical pathways: the time is here for pharmacist involvement. American College of Clinical Pharmacy.1996
- Opportunities and responsibilities in pharmaceutical careAmerican Journal of Health-System Pharmacy, 1990
- Documentation of clinical interactions: quality of care issues and economic considerations in critical care pharmacy.1988
- Cost-benefit of a clinical services integrated with a decentralized unit dose system.1988